title: [Effectiveness and safety of varenicline for smoking cessation].
abstract: Smoking is one of the major avoidable risks for mortality and morbidity. Thus                     developing new strategies for smoking cessation is a crucial medical challenge.                     Varenicline is an α4β2 nicotinic acetylcholine receptor                     partial agonist developed especially for smoking cessation. Several trials                     proved the efficacy of varenicline and its superiority to other medications for                     smoking cessation (bupropion and nicotine replacement therapy). Varenicline was                     associated with severe cardiovascular and neuro-psychiatric side effects. This                     article discusses the current research data on efficacy and safety of                     varenicline therapy for smoking cessation.
authors.affiliation: Abteilung Pharmakologie, Universitätsmedizin Göttingen.
authors.forename: P
authors.initials: P
authors.lastname: Christalla
authors.forename: M
authors.initials: M
authors.lastname: Dewenter
authors.forename: A
authors.initials: A
authors.lastname: El-Armouche
mesh_terms: D001552:Benzazepines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011810:Quinoxalines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000191:economics; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline